$DVA
DAVITA INC.

2022 Q3 Form 10-Q Financial Statement

#000092706622000133 Filed on August 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q4
Revenue $2.949B $2.927B $2.944B
YoY Change 0.35% 0.35% 1.33%
Cost Of Revenue $2.086B $2.017B $2.060B
YoY Change 3.83% 2.62% 0.16%
Gross Profit $863.1M $910.0M $883.7M
YoY Change -7.16% -4.34% 4.17%
Gross Profit Margin 29.27% 31.09% 30.02%
Selling, General & Admin $365.4M $315.2M $322.7M
YoY Change 24.69% 5.75% 5.98%
% of Gross Profit 42.34% 34.64% 36.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $194.4M $171.2M $174.8M
YoY Change 14.05% 0.88% 8.21%
% of Gross Profit 22.52% 18.81% 19.78%
Operating Expenses $559.9M $486.4M $497.5M
YoY Change 20.78% 3.98% 6.76%
Operating Profit $303.3M $432.7M $386.3M
YoY Change -36.14% -11.78% 1.2%
Interest Expense -$91.17M -$73.45M -$68.94M
YoY Change 42.18% 10.78% 12.46%
% of Operating Profit -30.06% -16.97% -17.85%
Other Income/Expense, Net -$4.898M -$1.284M -$2.388M
YoY Change -35.47% -108.45% -138.52%
Pretax Income $207.2M $348.8M $314.9M
YoY Change -47.47% -19.31% -3.81%
Income Tax $42.52M $64.23M $65.51M
% Of Pretax Income 20.52% 18.41% 20.8%
Net Earnings $105.4M $224.8M $187.5M
YoY Change -59.44% -23.49% 7.88%
Net Earnings / Revenue 3.57% 7.68% 6.37%
Basic Earnings Per Share $1.16 $2.38
Diluted Earnings Per Share $1.130M $2.30 $1.789M
COMMON SHARES
Basic Shares Outstanding 91.30M shares 94.46M shares 101.9M shares
Diluted Shares Outstanding 93.26M shares 97.77M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $441.8M $407.7M $533.7M
YoY Change -60.05% -63.41% 41.48%
Cash & Equivalents $367.5M $262.6M $461.9M
Short-Term Investments $74.31M $145.1M $71.82M
Other Short-Term Assets $160.5M $156.7M $165.6M
YoY Change -0.87% -32.53% -34.55%
Inventory $106.8M $109.5M $107.4M
Prepaid Expenses
Receivables $2.089B $2.094B $1.958B
Other Receivables $404.3M $502.9M $427.3M
Total Short-Term Assets $3.202B $3.264B $3.168B
YoY Change -16.59% -17.96% 0.6%
LONG-TERM ASSETS
Property, Plant & Equipment $5.962B $3.305B $3.480B
YoY Change 72.16% -5.19% -1.19%
Goodwill $7.023B $7.020B $7.046B
YoY Change 1.18% 1.1% 1.84%
Intangibles $179.7M $184.7M $177.7M
YoY Change 18.14% 13.7% 6.67%
Long-Term Investments $287.1M $298.0M $288.4M
YoY Change 3.73% 6.75% -0.55%
Other Assets $307.7M $257.6M $136.7M
YoY Change 203.26% 169.74% 71.92%
Total Long-Term Assets $13.76B $13.84B $13.95B
YoY Change -0.25% 0.03% 0.82%
TOTAL ASSETS
Total Short-Term Assets $3.202B $3.264B $3.168B
Total Long-Term Assets $13.76B $13.84B $13.95B
Total Assets $16.96B $17.10B $17.12B
YoY Change -3.81% -3.98% 0.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $417.1M $402.3M $402.0M
YoY Change 7.59% 6.92% -7.42%
Accrued Expenses $1.100B $958.2M $1.054B
YoY Change 2.67% -1.84% -0.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $214.3M $197.5M $179.0M
YoY Change 28.44% 7.09% 5.93%
Total Short-Term Liabilities $2.537B $2.311B $2.399B
YoY Change 7.38% -3.16% -3.13%
LONG-TERM LIABILITIES
Long-Term Debt $8.867B $9.065B $8.729B
YoY Change 1.1% 3.03% 10.26%
Other Long-Term Liabilities $2.665B $105.1M $119.2M
YoY Change 1534.61% -33.33% -20.59%
Total Long-Term Liabilities $11.53B $105.1M $119.2M
YoY Change 6972.9% -33.33% -20.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.537B $2.311B $2.399B
Total Long-Term Liabilities $11.53B $105.1M $119.2M
Total Liabilities $16.43B $14.94B $14.75B
YoY Change 10.4% 0.12% 4.67%
SHAREHOLDERS EQUITY
Retained Earnings $846.6M $741.3M $354.3M
YoY Change -48.49% -46.43% -58.44%
Common Stock $609.4M $578.4M $540.4M
YoY Change 16.06% 10.56% -9.51%
Preferred Stock
YoY Change
Treasury Stock (at cost) $787.9M $603.1M $0.00
YoY Change -12.41% 7.07%
Treasury Stock Shares
Shareholders Equity $532.7M $604.8M $755.5M
YoY Change
Total Liabilities & Shareholders Equity $16.96B $17.10B $17.12B
YoY Change -3.81% -3.98% 0.78%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income $105.4M $224.8M $187.5M
YoY Change -59.44% -23.49% 7.88%
Depreciation, Depletion And Amortization $194.4M $171.2M $174.8M
YoY Change 14.05% 0.88% 8.21%
Cash From Operating Activities $710.5M $188.1M $529.9M
YoY Change 25.32% -72.32% 9.3%
INVESTING ACTIVITIES
Capital Expenditures -$143.9M -$142.4M -$188.8M
YoY Change -9.03% -4.8% -15.93%
Acquisitions
YoY Change
Other Investing Activities -$9.921M -$2.513M -$147.7M
YoY Change 58.23% -74.25% 30.28%
Cash From Investing Activities -$153.9M -$144.9M -$336.5M
YoY Change -6.47% -9.06% -0.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -445.3M -103.4M -774.4M
YoY Change -4.07% -72.92% 66.49%
NET CHANGE
Cash From Operating Activities 710.5M 188.1M 529.9M
Cash From Investing Activities -153.9M -144.9M -336.5M
Cash From Financing Activities -445.3M -103.4M -774.4M
Net Change In Cash 111.4M -60.14M -581.0M
YoY Change -280.62% -143.36% 82.48%
FREE CASH FLOW
Cash From Operating Activities $710.5M $188.1M $529.9M
Capital Expenditures -$143.9M -$142.4M -$188.8M
Free Cash Flow $854.5M $330.5M $718.7M
YoY Change 17.83% -60.15% 1.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000927066
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97289000 shares
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
dva Corporate Integrity Agreement Period
CorporateIntegrityAgreementPeriod
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-14106
dei Entity Registrant Name
EntityRegistrantName
DAVITA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0354549
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 16th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
631-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91300000 shares
CY2022Q2 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2810099000 usd
CY2021Q2 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2817957000 usd
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
5526380000 usd
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
5532544000 usd
CY2022Q2 us-gaap Other Income
OtherIncome
116658000 usd
CY2021Q2 us-gaap Other Income
OtherIncome
98553000 usd
us-gaap Other Income
OtherIncome
217932000 usd
us-gaap Other Income
OtherIncome
203967000 usd
CY2022Q2 us-gaap Revenues
Revenues
2926757000 usd
CY2021Q2 us-gaap Revenues
Revenues
2916510000 usd
us-gaap Revenues
Revenues
5744312000 usd
us-gaap Revenues
Revenues
5736511000 usd
CY2022Q2 dva Patient Care Costs
PatientCareCosts
2016788000 usd
CY2021Q2 dva Patient Care Costs
PatientCareCosts
1965277000 usd
dva Patient Care Costs
PatientCareCosts
4035317000 usd
dva Patient Care Costs
PatientCareCosts
3903607000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
315219000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
298091000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
610039000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
579517000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
171176000 usd
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169689000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
344120000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
335390000 usd
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9141000 usd
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7023000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
16187000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15081000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
2494042000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
2426034000 usd
us-gaap Costs And Expenses
CostsAndExpenses
4973289000 usd
us-gaap Costs And Expenses
CostsAndExpenses
4803433000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
432715000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
490476000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
771023000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
933078000 usd
CY2022Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
82586000 usd
CY2021Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
73324000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
156377000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
140338000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1284000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15188000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3070000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16356000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
348845000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
432340000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
611576000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
809096000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64229000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81309000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
121242000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
166520000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
284616000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
351031000 usd
us-gaap Profit Loss
ProfitLoss
490334000 usd
us-gaap Profit Loss
ProfitLoss
642576000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
59807000 usd
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
57211000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
103403000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
111353000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
224809000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
293820000 usd
us-gaap Net Income Loss
NetIncomeLoss
386931000 usd
us-gaap Net Income Loss
NetIncomeLoss
531223000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.38
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.94
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.30
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94457000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106364000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95382000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107606000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97772000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111423000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99121000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112555000 shares
CY2022Q2 us-gaap Profit Loss
ProfitLoss
284616000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
351031000 usd
us-gaap Profit Loss
ProfitLoss
490334000 usd
us-gaap Profit Loss
ProfitLoss
642576000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
13217000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-2059000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
54349000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
2823000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
-1033000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
-1033000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
-2066000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
-2066000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-91176000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
57910000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-28964000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4634000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-76926000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
56884000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27451000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
255000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
207690000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
407915000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
517785000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
642831000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
59807000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
57211000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
103403000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
111353000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
147883000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
350704000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
414382000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
531478000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262605000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
461900000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
93132000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
93060000 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
100489000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
22310000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2093830000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1957583000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
109522000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
107428000 usd
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
502921000 usd
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
427321000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
63539000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
72517000 usd
CY2022Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
38070000 usd
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
25604000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
3264108000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
3167723000 usd
CY2022Q2 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
4989142000 usd
CY2021Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
4763135000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3304596000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3479972000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2771757000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2824787000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44985000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
60730000 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
184740000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
177693000 usd
CY2022Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
253457000 usd
CY2021Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
238881000 usd
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
44562000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
49514000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
257577000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
136677000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
7019778000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
7046241000 usd
CY2022Q2 us-gaap Assets
Assets
17100575000 usd
CY2021Q4 us-gaap Assets
Assets
17121488000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
402308000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
402049000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
752717000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
709345000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
559791000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
659960000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
398421000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
394357000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
197510000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
179030000 usd
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 usd
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
53792000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2310747000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2398533000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2606391000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2672713000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
9064916000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8729150000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
105137000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
119158000 usd
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
852389000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
830954000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
14939580000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
14750508000 usd
CY2022Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1385821000 usd
CY2021Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1434832000 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98179000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92206000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97289000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
98000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
97000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
578272000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
540321000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
741268000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
354337000 usd
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5973000 shares
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
603058000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-111796000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-139247000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
604784000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
755508000 usd
CY2022Q2 us-gaap Minority Interest
MinorityInterest
170390000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
180640000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
775174000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
936148000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17100575000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17121488000 usd
us-gaap Profit Loss
ProfitLoss
490334000 usd
us-gaap Profit Loss
ProfitLoss
642576000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
344120000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
335390000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
50109000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
51717000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
9069000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
40685000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-90000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
2764000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
32858000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1274000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
132043000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
117171000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1927000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3270000 usd
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
61811000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
49093000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-13232000 usd
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
-14465000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
13706000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24517000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47390000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-102513000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-90381000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
42517000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
25090000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-63638000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
10753000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6557000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
510316000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
834036000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
265461000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
294438000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
9491000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
23890000 usd
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
114829000 usd
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
29774000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
89530000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
7923000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
3010000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
2164000 usd
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
8415000 usd
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
7923000 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
3775000 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
11908000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
23806000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
6029000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
1047000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
1140000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-263232000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-283699000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1182911000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1611086000 usd
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
841687000 usd
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
754407000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
9089000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
617432000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
560507000 usd
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
118315000 usd
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
99362000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
47866000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
43605000 usd
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
9116000 usd
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
15925000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
3673000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
15365000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
4493000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-444965000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155548000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1342000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1197000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-199223000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
704688000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554960000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
501790000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355737000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1206478000 usd
CY2022Q2 us-gaap Revenues
Revenues
2926757000 usd
CY2021Q2 us-gaap Revenues
Revenues
2916510000 usd
us-gaap Revenues
Revenues
5744312000 usd
us-gaap Revenues
Revenues
5736511000 usd
dva Corporate Integrity Agreement Expiration Date
CorporateIntegrityAgreementExpirationDate
2019-10-22
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
224809000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
293820000 usd
us-gaap Net Income Loss
NetIncomeLoss
386931000 usd
us-gaap Net Income Loss
NetIncomeLoss
531223000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
94457000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
106364000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
95382000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
107606000 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3315000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5059000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3739000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4949000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97772000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111423000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99121000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112555000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.38
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.94
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.30
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1201000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
141000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
686000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
84000 shares
CY2022Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
104837000 usd
CY2022Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
40214000 usd
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
145051000 usd
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
23226000 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
48598000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
71824000 usd
CY2022Q2 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
89830000 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
100489000 usd
CY2021Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8227000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
22310000 usd
CY2022Q2 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
15007000 usd
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
44562000 usd
CY2021Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
14999000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
49514000 usd
CY2022Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
104837000 usd
CY2022Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
40214000 usd
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
145051000 usd
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
23226000 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
48598000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
71824000 usd
CY2020Q4 us-gaap Goodwill
Goodwill
6919109000 usd
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
173244000 usd
CY2021 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
1745000 usd
CY2021 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
-44367000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
7046241000 usd
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-1145000 usd
us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
3213000 usd
us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
-22105000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
7019778000 usd
CY2022Q2 us-gaap Goodwill Gross
GoodwillGross
7136340000 usd
CY2022Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
116562000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
7019778000 usd
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9312986000 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8964865000 usd
CY2022Q2 dva Discount Premium And Deferred Financing Costs
DiscountPremiumAndDeferredFinancingCosts
50560000 usd
CY2021Q4 dva Discount Premium And Deferred Financing Costs
DiscountPremiumAndDeferredFinancingCosts
56685000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
9262426000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8908180000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
197510000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
179030000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
9064916000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8729150000 usd
CY2022Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0368
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0341
CY2022Q2 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0410
CY2022Q2 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.50
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">contingencies</span><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of June 30, 2022 and December 31, 2021, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2016 U.S. Attorney Texas Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The government’s investigation covers the period from January 1, 2006 through December 31, 2018. In December 2017, the Company finalized and executed a settlement agreement that resolved certain of the issues in the government’s investigation and that included total monetary consideration of $63,700, as previously disclosed, of which $41,500 was an incremental cash payment and $22,200 was for amounts previously refunded, and all of which was previously accrued. The government’s investigation is ongoing with respect to issues related to DaVita Rx’s historic relationships with certain pharmaceutical manufacturers, and in July 2018 the Office of Inspector General (OIG) served the Company with a subpoena seeking additional documents and information relating to those relationships. On September 15, 2021, the U.S. Attorney’s Office notified the U.S. District Court, Northern District of Texas, of its decision and the decision of 31 states not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated September 17, 2021. The complaint was not served on the Company. In December 2021, the private party relator filed a notice of voluntary dismissal of all claims and the court entered an order dismissing the claims without prejudice. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Department of Justice Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, the Company received a CID from the Department of Justice pursuant to an FCA investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company’s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On October 18, 2021, the Company filed a motion to dismiss the class action complaint. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. No. 20-1641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On November 5, 2021, the United States Supreme Court granted certiorari of an appeal by an employer group health plan, the plan sponsor, and the plan’s advisor of the U.S. Court of Appeals for the Sixth Circuit (Sixth Circuit) decision in the Company's favor. The questions presented involved whether the health plan violates the Medicare Secondary Payor Act (MSPA) by "taking into account" that plan beneficiaries are eligible for Medicare and/or by "differentiating" between the benefits that the plan offers to patients with dialysis versus others. On December 23, 2021, the Solicitor General on behalf of the United States filed an amicus brief supporting the petitioners' request to overturn the Sixth Circuit decision. On January 19, 2022, the Company filed its brief in support of the Sixth Circuit decision. On June 21, 2022, the United States Supreme Court reversed the Sixth Circuit decision and held that the employee health plan for Marietta Memorial Hospital did not violate the MSPA. The case will be remanded back to the lower court for resolution of the outstanding claims. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 7, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div>
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
191666000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2022Q2 dva Business Acquisition Goodwill Expected Tax Deductible Amount Adjustment
BusinessAcquisitionGoodwillExpectedTaxDeductibleAmountAdjustment
-1145000 usd
CY2022Q2 dva Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple
PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple
175000000 usd
CY2022Q2 us-gaap Revenues
Revenues
2926757000 usd
CY2021Q2 us-gaap Revenues
Revenues
2916510000 usd
us-gaap Revenues
Revenues
5744312000 usd
us-gaap Revenues
Revenues
5736511000 usd
CY2022Q2 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
30973000 usd
CY2021Q2 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
25495000 usd
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
66800000 usd
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
50940000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
432715000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
490476000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
771023000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
933078000 usd
CY2022Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
82586000 usd
CY2021Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
73324000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
156377000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
140338000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1284000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
344120000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15188000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3070000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16356000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
348845000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
432340000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
611576000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
809096000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
171176000 usd
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169689000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
335390000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
265461000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
294438000 usd
CY2022Q2 us-gaap Assets
Assets
17100575000 usd
CY2021Q4 us-gaap Assets
Assets
17121488000 usd

Files In Submission

Name View Source Status
0000927066-22-000133-index-headers.html Edgar Link pending
R41.htm Edgar Link pending
0000927066-22-000133-index.html Edgar Link pending
0000927066-22-000133.txt Edgar Link pending
0000927066-22-000133-xbrl.zip Edgar Link pending
dva-20220630.htm Edgar Link pending
dva-20220630.xsd Edgar Link pending
dva-20220630_cal.xml Edgar Link unprocessable
dva-20220630_def.xml Edgar Link unprocessable
dva-20220630_g1.jpg Edgar Link pending
dva-20220630_htm.xml Edgar Link completed
dva-20220630_lab.xml Edgar Link unprocessable
dva-20220630_pre.xml Edgar Link unprocessable
dva-63022ex31110xq.htm Edgar Link pending
dva-63022ex31210xq.htm Edgar Link pending
dva-63022ex32110xq.htm Edgar Link pending
dva-63022ex32210xq.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending